SCHEMBL22492438

SCHEMBL22492438

CCc1cccc2c(C(=O)O)ccnc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
L3MBTL1 Q9Y468 4/20 0.64
KDM4A O75164 2/20 0.64
EGLN1 Q9GZT9 2/20 0.64
RAB9A P51151 1/20 0.64
HIF1AN Q9NWT6 1/20 0.64
PSMD14 O00487 2/20 0.60
KDM4C Q9H3R0 2/20 0.51
KDM6B O15054 1/20 0.51
KDM6A O15550 1/20 0.51
TET3 O43151 1/20 0.51
KDM4B O94953 1/20 0.51
KDM5C P41229 1/20 0.51
KDM4D Q6B0I6 1/20 0.51
TET2 Q6N021 1/20 0.51
ALKBH5 Q6P6C2 1/20 0.51
TET1 Q8NFU7 1/20 0.51
FTO Q9C0B1 1/20 0.51
KDM2A Q9Y2K7 1/20 0.51
KDM3A Q9Y4C1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22492361 0.83 PSMD14 (0.66) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL15473079 0.83 SLC40A1 (0.55) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL69905 0.81 KDM4E (0.74) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL5761539 0.80 KDM4E (0.68) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL19725754 0.79 KDM4E (0.50) KDM4EL3MBTL1RAB9APSMD14LMNA
SCHEMBL7372534 0.79 KDM4E (0.66) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL9655531 0.78 HAVCR2 (0.44) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL298623 0.78 KDM4E (1.00) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL474238 0.78 KDM4E (0.50) KDM4EL3MBTL1KDM4AEGLN1RAB9A
SCHEMBL442207 0.77 HAVCR2 (0.65) KDM4ERAB9ACLCN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2022-07-07 US disclosed
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases THE ROCKEFELLER UNIVERSITY (US) 2022-04-26 US disclosed
US-20200369677-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2020-11-26 US disclosed
EP-3716972-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES The Rockefeller University (US) 2020-10-07 EP disclosed
CN-111670034-A Pyranopyrazoles and pyrazolopyridines immunomodulators for the treatment of autoimmune diseases 洛克菲勒大学 2020-09-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369677-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI, TFPI2, SERPINC1 KDM4E 3175/4885L3MBTL1 4831/4885KDM4A 3433/4885
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases TFPI, TFPI2, SERPINC1 KDM4E 3175/4885L3MBTL1 4831/4885KDM4A 3433/4885
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI, TFPI2, SERPINC1 KDM4E 3175/4885L3MBTL1 4831/4885KDM4A 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.